Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of WH007 in polycystic ovary syndrome
ChiCTR2600130343Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ramulus mori alkaloids in polycystic ovary syndrome (PCOS) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Ovulation rate at Week 24 and Hirsutism and acne scoring. Started Aug 2026; status: recruiting.
02
Drugs
ramulus mori alkaloids
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on ChiCTR2600130343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130343.